Publications: DR Marco Gerlinger

Flanders L, Savy T, Ficial M, Al-Ghraibawi N, Barber L, Slater S, Pihlak R, Propper D et al. ( 2026 ) . PD-L1 CPS in gastroesophageal cancer: differences in routine care versus Checkmate 649 and implications for biopsy-site choice and assay standardisation . British Journal of Cancer1 - 8 .

Millar L, Di Marco Barros R, Kapiris M, Nikolaou C, Gerlinger M, Wu Y ( 2025 ) . Clinical and experimental treatment of advanced melanoma with a focus on immunotherapy . Clinical & Experimental Immunology vol. 219 , ( 1 )

Ogden S, Metic N, Leylek O, Smith EA, Berner AM, Baker A-M, Uddin I, Buzzetti M et al. ( 2025 ) . Phenotypic heterogeneity and plasticity in colorectal cancer metastasis . Cell Genomics vol. 5 , ( 7 )

Bashir U, Wang C, Smillie R, Khan AKR, Ahmed HT, Ordidge K, Power N, Gerlinger M et al. ( 2025 ) . Deep learning for liver lesion segmentation and classification on staging CT scans of colorectal cancer patients: a multi-site technical validation study . Clinical Radiology vol. 85 ,

Savy T, Flanders L, Karpanasamy T ( 2025 ) . Cancer evolution: from Darwin to the Extended Evolutionary Synthesis . Trends in Cancer vol. 11 , ( 3 ) 204 - 215 .

Seyedi S, Harris VK, Kapsetaki SE, Narayanan S, Saha D, Compton Z, May A, Fakir E et al. ( 2024 ) . Resistance Management for Cancer: Lessons from Farmers . Cancer Research vol. 84 , ( 22 ) 3715 - 3727 .

Saeed A, Tabernero J, Parikh A, Van den Eynde M, Karthaus M, Wang G, Hecht JR ( 2024 ) . STELLAR-303: randomized phase III study of zanzalintinib + atezolizumab in previously treated metastatic colorectal cancer . Future Oncology vol. 20 , ( 24 ) 1733 - 1743 .

Lane R, Mencel J, Turkes F, Challoner BR, McCafferty N, Ntellas P, Barber LJ, Rana I et al. ( 2024 ) . 124P Acquired resistance to first-line chemo- and EGFRab-therapy in mCRC: Biopsy analysis of the iSCORE trial . Annals of Oncology . vol. 35 ,

Challoner BR, Slater SC, Sansano HB, Aresu M, Bryant A, Begum R, Rana T, Zhitkov O et al. ( 2024 ) . 30P Immunological markers of pathological and clinical and outcomes in mismatch repair deficient (MMRd) colorectal cancer (CRC) . Annals of Oncology . vol. 35 ,

Mencel J, Alves A, Angelis V, Gerlinger M, Starling N ( 2024 ) . State of the art: Targeting microsatellite instability in gastrointestinal cancers . Critical Reviews in Oncology/Hematology vol. 199 ,

Buzzetti M, Gerlinger M ( 2023 ) . Assessing the toxicity of bispecific antibodies . Nature Biomedical Engineering vol. 8 , ( 4 ) 339 - 340 .

Newey A, Yu L, Barber LJ ( 2023 ) . Multifactorial Remodeling of the Cancer Immunopeptidome by IFNγ . Cancer Research Communications vol. 3 , ( 11 ) 2345 - 2357 .

Challoner BR, Woolston A, Lau D, Buzzetti M, Fong C, Barber LJ, Anandappa G, Crux R et al. ( 2023 ) . Genetic and immune landscape evolution in MMR‐deficient colorectal cancer . The Journal of Pathology vol. 262 , ( 2 ) 226 - 239 .

Mencel J, Turkes F, Barber L, Challoner B, Buzzetti M, Tran A, Chen H, McCafferty N et al. ( 2023 ) . P-111 PD1 and LAG3 inhibition as second+ line treatment after EGFR antibody-containing therapy in RAS/BRAF wildtype, MMRp metastatic colorectal cancer . Annals of Oncology . vol. 34 , s53 - s54 .

Alexander JL, Posma JM, Scott A, Poynter L, Mason SE, Doria ML, Herendi L, Roberts L et al. ( 2023 ) . Pathobionts in the tumour microbiota predict survival following resection for colorectal cancer . Microbiome vol. 11 , ( 1 )

Gerlinger M, Gordon A, Barber LJ, Laliotis G, Athauda A, Challoner B, Woolston A, Mansukhani S et al. ( 2023 ) . Abstract 5591: Circulating tumor DNA for recurrence prediction and efficacy analysis in the ICONIC trial of peri-operative FLOT and avelumab (PD-L1) in localized esophago-gastric adenocarcinoma . Cancer Research . vol. 83 , 5591 - 5591 .

McCafferty N, Fong C, Barber LJ, Woolston A, Kleftogiannis D, Cromarty S, Kidd S, Begum R ( 2023 ) . Abstract 5593: Clonal mutation burden and evolutionary dynamics analysis in metastatic gastro-esophageal adenocarcinoma (GEA) by error corrected whole-exome circulating tumor DNA sequencing . Cancer Research . vol. 83 , 5593 - 5593 .

Athauda A, Silveira T, Lund T, von Loga K, Challoner B, Rana I, Thomas J, Starling N et al. ( 2023 ) . Impact of infiltrating T cell subtypes on survival and response to FLOT chemotherapy in resectable oesophagogastric adenocarcinoma (OGA) . Journal of Clinical Oncology vol. 41 , ( 4_suppl ) 443 - 443 .

Gordon A, Challoner B, Athauda A, Woolston A, Mansukhani S, Dunstan M, Petrou N, Khabra K et al. ( 2023 ) . Primary results of the ICONIC phase 2 trial of perioperative FLOT plus avelumab (FLOT-A) in operable oesophagogastric adenocarcinoma (OGA) . Journal of Clinical Oncology vol. 41 , ( 4_suppl ) 446 - 446 .

Torlot L, Jarzab A, Albert J, Pók-Udvari Á, Stahler A, Holch JW, Gerlinger M, Heinemann V et al. ( 2022 ) . Proteomics uncover EPHA2 as a potential novel therapeutic target in colorectal cancer cell lines with acquired cetuximab resistance . Journal of Cancer Research and Clinical Oncology vol. 149 , ( 2 ) 669 - 682 .

Lote H, Starling N, Pihlak R, Gerlinger M ( 2022 ) . Advances in immunotherapy for MMR proficient colorectal cancer . Cancer Treatment Reviews vol. 111 ,

Büttner FA, Winter S, Stühler V, Rausch S, Hennenlotter J, Füssel S, Zastrow S, Meinhardt M et al. ( 2022 ) . A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy . Genome Medicine vol. 14 , ( 1 )

Dankner M, Wang Y, Fazelzad R, Johnson B, Nebhan CA, Dagogo-Jack I, Richtig G, Bracht JWP et al. ( 2022 ) . Clinical Activity of Mitogen-Activated Protein Kinase–Targeted Therapies in Patients With Non–V600 BRAF-Mutant Tumors . JCO Precision Oncology vol. 6 , ( 6 )

Somarelli JA, DeGregori J, Gerlinger M, Heng HH, Marusyk A, Welch DR, Laukien FH ( 2022 ) . Questions to guide cancer evolution as a framework for furthering progress in cancer research and sustainable patient outcomes . Medical Oncology vol. 39 , ( 9 )

Challoner BR, Woolston A, Lau D, Buzzetti M, Barber LJ, Lund T, Sansano HB, von Loga K et al. ( 2022 ) . Abstract A002: Genetic and immune landscape evolution defines subtypes of MMR deficient colorectal cancer . Cancer Research . vol. 82 , a002 - a002 .

Challoner BR, Woolston A, Lau D, Buzzetti M, Barber LJ, Lund T, Sansano HB, von Loga K et al. ( 2022 ) . Abstract PR012: Genetic and immune landscape evolution defines subtypes of MMR deficient colorectal cancer . Cancer Research . vol. 82 , pr012 - pr012 .

Moussa O, Bhogal RH, Malietzis G, Fribbens C, Starling N, Gerlinger M, Watkins D, Chau I et al. ( 2022 ) . Effect of perioperative FLOT versus ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma: propensity score-matched study . BJS Open vol. 6 , ( 1 )

Woolston A, Barber LJ, Griffiths B, Pich O, Lopez-Bigas N, Matthews N, Rao S, Watkins D et al. ( 2021 ) . Mutational signatures impact the evolution of anti-EGFR antibody resistance in colorectal cancer . Nature Ecology & Evolution vol. 5 , ( 7 ) 1024 - 1032 .

Dujon AM, Aktipis A, Alix‐Panabières C, Amend SR, Boddy AM, Brown JS, Capp J, DeGregori J et al. ( 2021 ) . Identifying key questions in the ecology and evolution of cancer . Evolutionary Applications vol. 14 , ( 4 ) 877 - 892 .

Gerlinger M ( 2021 ) . Immunotherapy Sensitivity of Mismatch Repair-Deficient Cancer: Mutation Load Is Not Enough . Cancer Cell vol. 39 , ( 1 ) 16 - 18 .

Knebel FH, Barber LJ, Newey A, Kleftogiannis D, Woolston A, Fenwick K, Bettoni F, Ribeiro MFSA et al. ( 2020 ) . Circulating Tumour DNA Sequencing Identifies a Genetic Resistance-Gap in Colorectal Cancers with Acquired Resistance to EGFR-Antibodies and Chemotherapy . Cancers vol. 12 , ( 12 )

Khan K, Gonzalez-Exposito R, Cunningham D, Koh D-M, Woolston A, Barber L, Griffiths B, Kouvelakis K et al. ( 2020 ) . Diagnostic Accuracy and Safety of Coaxial System in Oncology Patients Treated in a Specialist Cancer Center With Prospective Validation Within Clinical Trial Data . Frontiers in Oncology vol. 10 ,

Fotiadis N, De Paepe KN, Bonne L, Khan N, Riddell A, Turner N, Starling N, Gerlinger M et al. ( 2020 ) . Comparison of a coaxial versus non-coaxial liver biopsy technique in an oncological setting: diagnostic yield, complications and seeding risk . European Radiology vol. 30 , ( 12 ) 6702 - 6708 .

Angelis V, Tippu Z, Joshi K, Reis S, Gronthoud F, Fribbens C, Okines A, Stanway S et al. ( 2020 ) . Defining the true impact of coronavirus disease 2019 in the at-risk population of patients with cancer . European Journal of Cancer vol. 136 , 99 - 106 .

Masotti C, Knebel FH, Linck RDM, Lima J, Shimada AK, Alessi JV, Zucchetti BM, Gerlinger M et al. ( 2020 ) . Abstract A19: Detection of ESR1 mutations in plasma cell-free DNA from metastatic ER-positive breast cancer patients resistant to hormone therapy . Clinical Cancer Research vol. 26 , ( 11_Supplement ) a19 - a19 .

Challoner BR, von Loga K, Woolston A, Griffiths B, Sivamanoharan N, Semiannikova M, Newey A, Barber LJ et al. ( 2020 ) . Computational Image Analysis of T-Cell Infiltrates in Resectable Gastric Cancer: Association with Survival and Molecular Subtypes . Journal of the National Cancer Institute vol. 113 , ( 1 ) 88 - 98 .

Lau D, Kalaitzaki E, Church DN, Pandha H, Tomlinson I, Annels N, Gerlinger M, Sclafani F et al. ( 2020 ) . Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study . ESMO Open vol. 5 , ( 1 )

Cartwright E, Fong CYK, Hubank M, Saffery C, Kalaitzaki E, Young K, Coyne T, Musallam A et al. ( 2020 ) . SOlar: A translational phase II study of single-agent olaparib in the treatment of advanced esophagogastric cancer . Journal of Clinical Oncology vol. 38 , ( 4_suppl ) tps471 - tps471 .

von Loga K, Woolston A, Punta M, Barber LJ, Griffiths B, Semiannikova M, Spain G, Challoner B et al. ( 2020 ) . Author Correction: Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer . Nature Communications vol. 11 , ( 1 )

von Loga K, Woolston A, Punta M, Barber LJ, Griffiths B, Semiannikova M, Spain G, Challoner B et al. ( 2020 ) . Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer . Nature Communications vol. 11 , ( 1 )

Gerlinger M ( 2019 ) . Targeted drugs ramp up cancer mutability . vol. 366 , is. 6472 , pp. 1452 - 1453 . American Association for the Advancement of Science (AAAS)

Newey A, Griffiths B, Michaux J, Pak HS, Stevenson BJ, Woolston A, Semiannikova M, Spain G et al. ( 2019 ) . Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment . Journal for ImmunoTherapy of Cancer vol. 7 , ( 1 )

Turkes FS, Crux R, Cunningham D, Athauda A, Kalaitzaki E, Musallam A, Begum R, De Paepe K et al. ( 2019 ) . 661TiP iSCORE: Immunotherapy sequencing in colon and rectal cancer . Annals of Oncology vol. 30 ,

Davidson M, Mansukhani S, Starling N, Chau I, Watkins D, Cunningham D, Rao S, Lazaro-Alcausi R et al. ( 2019 ) . 674PD Perioperative FLOT + anti-PD-L1 avelumab (FLOT-A) chemo-immunotherapy in resectable oesophagogastric adenocarcinoma (OGA): Safety and biomarker data from the ICONIC trial safety run-in . Annals of Oncology vol. 30 ,

Woolston A, Khan K, Spain G, Barber LJ, Griffiths B, Gonzalez-Exposito R, Hornsteiner L, Punta M et al. ( 2019 ) . Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer . Cancer Cell vol. 36 , ( 1 ) 35 - 50.e9 .

Davidson M, Barber LJ, Woolston A, Cafferkey C, Mansukhani S, Griffiths B, Moorcraft S-Y, Rana I et al. ( 2019 ) . Detecting and Tracking Circulating Tumour DNA Copy Number Profiles during First Line Chemotherapy in Oesophagogastric Adenocarcinoma . Cancers vol. 11 , ( 5 )

Gonzalez-Exposito R, Semiannikova M, Griffiths B, Khan K, Woolston A, Spain G, von Loga K, Challoner B et al. ( 2019 ) . CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids . Journal for ImmunoTherapy of Cancer vol. 7 , ( 1 )

Exposito RG, Semmianikova M, Griffiths B, Khan KH, Barber LJ, Woolston A, Spain G, von Loga K et al. ( 2019 ) . CEA expression patterns determine response and resistance to the CEA-TCB bispecific immunotherapy antibody in colorectal cancer patient derived organoids . Journal of Clinical Oncology vol. 37 , ( 4_suppl ) 535 - 535 .

Mansukhani S, Barber LJ, Kleftogiannis D, Moorcraft SY, Davidson M, Woolston A, Proszek PZ, Griffiths B et al. ( 2018 ) . Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing . Clinical Chemistry vol. 64 , ( 11 ) 1626 - 1635 .

Khan K, Rane JK, Cunningham D, Rao S, Watkins D, Starling N, Kalaitzaki E, Forster M et al. ( 2018 ) . Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies: Large Single-Center Experience . Clinical Colorectal Cancer vol. 18 , ( 1 ) 64 - 71.e1 .

Gerlinger M ( 2018 ) . Metastasis Seeding Cells: Lone Invaders or Mass Migrators? . Clinical Cancer Research vol. 24 , ( 9 ) 2032 - 2034 .

De Paepe K, Bonne L, Fotiadis N, Starling N, Chau I, Gerlinger M, Rao S, Watkins DJ et al. ( 2018 ) . Complications and seeding risk after percutaneous liver biopsy in an oncological setting . Journal of Clinical Oncology . vol. 36 , 246 - 246 .

Bonne L, De Paepe K, Fotiadis N, Starling N, Chau I, Gerlinger M, Rao S, Watkins DJ et al. ( 2018 ) . Percutaneous radiofrequency versus microwave ablation for the treatment of colorectal liver metastases . Journal of Clinical Oncology . vol. 36 , 401 - 401 .

Moorcraft SY, de Castro DG, Cunningham D, Jones T, Walker BA, Peckitt C, Yuan LC, Frampton M et al. ( 2018 ) . Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice . Annals of Oncology vol. 29 , ( 1 ) 230 - 236 .

Khakoo S, Georgiou A, Gerlinger M, Cunningham D, Starling N ( 2017 ) . Circulating tumour DNA, a promising biomarker for the management of colorectal cancer . Critical Reviews in Oncology/Hematology vol. 122 , 72 - 82 .

Lawler M, Alsina D, Adams RA, Anderson AS, Brown G, Fearnhead NS, Fenwick SW, Halloran SP et al. ( 2017 ) . Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer . Gut vol. 67 , ( 1 )

Kayhanian H, Goode E, Sclafani F, Ang JE, Gerlinger M, de Castro DG, Shepherd S, Peckitt C et al. ( 2017 ) . Treatment and Survival Outcome of BRAF-Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case-Control Study . Clinical Colorectal Cancer vol. 17 , ( 1 ) e69 - e76 .

Maley CC, Aktipis A, Graham TA, Sottoriva A, Boddy AM, Janiszewska M, Silva AS, Gerlinger M et al. ( 2017 ) . Classifying the evolutionary and ecological features of neoplasms . Nature Reviews Cancer vol. 17 , ( 10 ) 605 - 619 .

von Loga K, Gerlinger M ( 2017 ) . Cancer (r)evolution . Nature Ecology & Evolution vol. 1 , ( 8 ) 1051 - 1052 .

Linch M, Goh G, Hiley C, Shanmugabavan Y, McGranahan N, Rowan A, Wong YNS, King H et al. ( 2017 ) . Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters . Annals of Oncology vol. 28 , ( 10 ) 2472 - 2480 .

Davies MN, Barber LJ, Spain G, Lopes F, Loga KV, Griffiths B, Woolston A, Alpar D et al. ( 2017 ) . Abstract 422: Lymph node metastasis evolution drives immune evasion and targeted therapy resistance in gastro-esophageal adenocarcinomas (GEAs) . Cancer Research . vol. 77 , 422 - 422 .

Khan K, Expósito RG, Cunningham D, Koh D-M, Woolston A, Kouvelakis K, Bali M, Mccall J et al. ( 2017 ) . PD-015 Diagnostic accuracy and safety of coaxial core-needle biopsy (CNB) system in a predominanty gastrointestinal oncology patient population, treated at the Royal Marsden (RM) Hospital . Annals of Oncology vol. 28 ,

Gerber T, Barber L, Huetter S, Bogen D, Davies M, Assiotis I, Berneder M, Abbasi R et al. ( 2017 ) . Visualization of intra tumor heterogeneity by simultaneous analysis of tumor and liquid biopsy samples in stage M neuroblastomas . Klinische Pädiatrie . Conference: 30. Jahrestagung der Kind-Philipp-Stiftung für pädiatrisch-onkologische Forschung vol. 229 , 182 - 195 .

Crusz SM, Tang YZ, Sarker S-J, Prevoo W, Kiyani I, Beltran L, Peters J, Sahdev A et al. ( 2016 ) . Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma . BMC Medicine vol. 14 , ( 1 )

Khan KH, Rata M, Koh D-M, Tunariu N, Collins DJ, Chau I, Watkins DJ, Starling N et al. ( 2016 ) . A prospective translational study investigating molecular predictors of resistance and response to regorafenib (REG) monotherapy in RAS mutant (mt) metastatic colorectal cancer (mCRC): Initial magnetic resonance imaging (MRI) sub-study result . Journal of Clinical Oncology . vol. 34 , 580 - 580 .

Lipinski KA, Barber LJ, Davies MN, Ashenden M ( 2016 ) . Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine . Trends in Cancer vol. 2 , ( 1 ) 49 - 63 .

Alpar D, Barber LJ ( 2015 ) . Genetic Intratumor Heterogeneity . Epigenetic Cancer Therapy ,

Khan K, Chau I, Gerlinger M, Valeri N, Koh D-M, Starling N, Watkins D, Rao S et al. ( 2015 ) . P-309 PROSPECT-R: A PROSPECTive translational study investigating molecular predictors of resistance and response to Regorafenib (REG) monotherapy in RAS mutant (mt) metastatic colorectal cancer (CRC) . Annals of Oncology . vol. 26 ,

Favero F, McGranahan N, Salm M, Birkbak NJ, Sanborn JZ, Benz SC, Becq J, Peden JF et al. ( 2015 ) . Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome . Annals of Oncology vol. 26 , ( 5 ) 880 - 887 .

Kanu N, Grönroos E, Martinez P, Burrell RA, Yi Goh X, Bartkova J, Maya-Mendoza A, Mistrík M et al. ( 2015 ) . SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair . Oncogene vol. 34 , ( 46 ) 5699 - 5708 .

Gerlinger M ( 2015 ) . Translating Seminoma Genomic Landscapes into Clinical Practice . European Urology vol. 68 , ( 1 ) 84 - 85 .

Davies MN, Alpar D, Griffiths B, Barber LJ, Lipinski KA, Eltahir Z, Wotherspoon A ( 2015 ) . Intratumor heterogeneity of DNA copy number aberrations in gastric and oesophageal adenocarcinomas . Journal of Clinical Oncology . vol. 33 , 78 - 78 .

Alpar D, Barber LJ ( 2015 ) . Chapter 24 Genetic Intratumor Heterogeneity . Epigenetic Cancer Therapy , Elsevier

Barber LJ, Davies MN ( 2014 ) . Dissecting cancer evolution at the macro-heterogeneity and micro-heterogeneity scale . Current Opinion in Genetics & Development vol. 30 , 1 - 6 .

de Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC, Yates L, Jamal-Hanjani M, Shafi S et al. ( 2014 ) . Spatial and temporal diversity in genomic instability processes defines lung cancer evolution . Science vol. 346 , ( 6206 ) 251 - 256 .

Gerlinger M, McGranahan N, Dewhurst SM, Burrell RA, Tomlinson I, Swanton C ( 2014 ) . Cancer: Evolution Within a Lifetime . Annual Review of Genetics vol. 48 , ( 1 ) 1 - 22 .

Mateo J, Gerlinger M, Rodrigues DN, de Bono JS ( 2014 ) . The promise of circulating tumor cell analysis in cancer management . Genome Biology vol. 15 , ( 8 )

Fisher R, Horswell S, Rowan A, Salm MP, de Bruin EC, Gulati S, McGranahan N, Stares M et al. ( 2014 ) . Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution . Genome Biology vol. 15 , ( 8 )

Gulati S, Martinez P, Joshi T, Birkbak NJ, Santos CR, Rowan AJ, Pickering L, Gore M et al. ( 2014 ) . Systematic Evaluation of the Prognostic Impact and Intratumour Heterogeneity of Clear Cell Renal Cell Carcinoma Biomarkers . European Urology vol. 66 , ( 5 ) 936 - 948 .

Gerlinger M, Catto JW, Orntoft TF, Real FX, Zwarthoff EC, Swanton C ( 2014 ) . Intratumour Heterogeneity in Urologic Cancers: From Molecular Evidence to Clinical Implications . European Urology vol. 67 , ( 4 ) 729 - 737 .

Gerlinger M, Horswell S, Larkin J, Rowan AJ, Salm MP, Varela I, Fisher R, McGranahan N et al. ( 2014 ) . Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing . Nature Genetics vol. 46 , ( 3 ) 225 - 233 .

Sharpe K, Stewart GD, Mackay A, Van Neste C, Rofe C, Berney D, Kayani I, Bex A et al. ( 2013 ) . The Effect of VEGF-Targeted Therapy on Biomarker Expression in Sequential Tissue from Patients with Metastatic Clear Cell Renal Cancer . Clinical Cancer Research vol. 19 , ( 24 ) 6924 - 6934 .

Martinez P, McGranahan N, Birkbak NJ, Gerlinger M, Swanton C ( 2013 ) . Computational optimisation of targeted DNA sequencing for cancer detection . Scientific Reports vol. 3 , ( 1 )

Gerlinger M, Quezada SA, Peggs KS, Furness AJ, Fisher R, Marafioti T, Shende VH, McGranahan N et al. ( 2013 ) . Ultra‐deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas . The Journal of Pathology vol. 231 , ( 4 ) 424 - 432 .

Gerlinger M, Norton L, Swanton C ( 2013 ) . Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1 . The New England Journal of Medicine vol. 369 , ( 12 ) 1172 - 1173 .

Awad MM, Engelman JA, Shaw AT ( 2013 ) . Acquired resistance to crizotinib from a mutation in CD74-ROS1 . The New England journal of medicine vol. 369 , ( 12 )

Martinez P, Birkbak NJ, Gerlinger M, McGranahan N, Burrell RA, Rowan AJ, Joshi T, Fisher R et al. ( 2013 ) . Parallel evolution of tumour subclones mimics diversity between tumours . The Journal of Pathology vol. 230 , ( 4 ) 356 - 364 .

Khattak MA, Bakr F, Krzystanek M, Szallasi Z, Gerlinger M, Santos C, Swanton C, Pickering LM et al. ( 2013 ) . Prognostic and Predictive Markers in Metastatic Renal Cell Carcinoma . Journal of Clinical Oncology vol. 31 , ( 7 ) 971 - 972 .

Swanton C, Larkin J, Gerlinger M ( 2012 ) . The authors reply . New England Journal of Medicine vol. 366 , ( 22 )

Gerlinger M, Santos CR, Spencer‐Dene B, Martinez P, Endesfelder D, Burrell RA, Vetter M, Jiang M et al. ( 2012 ) . Genome‐wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target . The Journal of Pathology vol. 227 , ( 2 ) 146 - 156 .

Yap TA, Gerlinger M, Futreal PA, Pusztai L, Swanton C ( 2012 ) . Intratumor Heterogeneity: Seeing the Wood for the Trees . Science Translational Medicine vol. 4 , ( 127 )

Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, Gronroos E, Martinez P et al. ( 2012 ) . Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing . The New England Journal of Medicine vol. 366 , ( 10 ) 883 - 892 .

Gerlinger M, Swanton C ( 2010 ) . How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine . vol. 103 , is. 8 , pp. 1139 - 1143 . Springer Nature

Gerlinger M, Wilson P, Shamash J ( 2010 ) . Elevated LDH predicts poor outcome of recurrent germ cell tumours treated with dose dense chemotherapy . European Journal of Cancer vol. 46 , ( 16 ) 2913 - 2918 .

Swanton C, Larkin JM, Gerlinger M, Eklund AC, Howell M, Stamp G, Downward J, Gore M et al. ( 2010 ) . Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets . Genome Medicine vol. 2 , ( 8 )

Tan DS-W, Gerlinger M, Teh B-T, Swanton C ( 2010 ) . Anti-cancer drug resistance: Understanding the mechanisms through the use of integrative genomics and functional RNA interference . European Journal of Cancer vol. 46 , ( 12 ) 2166 - 2177 .

Juul N, Szallasi Z, Eklund AC, Li Q, Burrell RA, Gerlinger M, Valero V, Andreopoulou E et al. ( 2010 ) . Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials . The Lancet Oncology vol. 11 , ( 4 ) 358 - 365 .

Gerlinger M, Rohatiner AZS, Matthews J, Davies A ( 2010 ) . Surveillance investigations after high-dose therapy with stem cell rescue for recurrent follicular lymphoma have no impact on management . Haematologica vol. 95 , ( 7 ) 1130 - 1135 .

Gerlinger M, Wilson P, Powles T, Oliver RTD, Shamash J ( 2009 ) . 951 ESTABLISHED PROGNOSTIC MODELS FAIL TO PREDICT THE OUTCOME OF DOSE DENSE CHEMOTHERAPY FOR THE TREATMENT OF RECURRENT GERM CELL TUMOURS (GCTS) . European Urology Open Science vol. 8 , ( 4 )

Gerlinger M, Matthews J, Lister TA, Montoto S ( 2008 ) . Active Surveillance Strategies Have Neither Clinical or Survival Benefit Following High-Dose Chemotherapy and Progenitor Cell Rescue in Follicular Lymphoma . Blood vol. 112 , ( 11 )

Gerlinger M, Wilson P, Powles T, Shamash J ( 2008 ) . Non-castrate status at the end of chemotherapy for metastatic hormone-resistant prostate cancer (HRPC) correlates with a better overall survival . Journal of Clinical Oncology vol. 26 , ( 15_suppl ) 16102 - 16102 .

Walton SM, Gerlinger M, de la Rosa O, Nuber N, Knights A, Gati A, Laumer M, Strauss L et al. ( 2006 ) . Spontaneous CD8 T Cell Responses against the Melanocyte Differentiation Antigen RAB38/NY-MEL-1 in Melanoma Patients . The Journal of Immunology vol. 177 , ( 11 ) 8212 - 8218 .

Kumbrink J, Gerlinger M, Johnson JP ( 2005 ) . Egr-1 Induces the Expression of Its Corepressor Nab2 by Activation of the Nab2 Promoter Thereby Establishing a Negative Feedback Loop* . Journal of Biological Chemistry vol. 280 , ( 52 ) 42785 - 42793 .

Khan K, exposito RG, Cunningham D, Koh D-M, Woolston A, Barber L, Griffins B, Kouvelakis K et al. . Diagnostic accuracy and safety of coaxial core-needle biopsy (CNB) system in Oncology patients treated in a specialist cancer centre with prospective validation within clinical trial data .

von Loga K, Woolston A, Punta M, Barber L, Griffiths B, Semiannikova M, Spain G, Challoner B et al. . Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer .

Challoner BR, Woolston A, Lau D, Buzzetti M, Fong C, Barber LJ, Anandappa G, Crux R et al. . Genetic and immune landscape evolution defines subtypes of MMR deficient colorectal cancer .

Woolston A, Khan K, Spain G, Barber LJ, Griffiths B, Exposito RG, Patil Y, Mansukhani S et al. . Genomic and transcriptomic determinants of therapy resistance and immune landscape evolution during anti-EGFR treatment in colorectal cancer .

Newey A, Yu L, Barber LJ, Choudhary JS, Bassani-Sternberg M, Gerlinger M . Multifactorial remodeling of the cancer immunopeptidome by interferon gamma .

Woolston A, Barber LJ, Griffiths B, Matthews N, Rao S, Watkins D, Chau I, Starling N et al. . Mutational processes impact the evolution of anti-EGFR antibody resistance in colorectal cancer .

Mansukhani S, Barber LJ, Moorcraft SY, Davidson M, Woolston A, Griffiths B, Fenwick K, Herman B et al. . Ultra-sensitive mutation detection and genome-wide DNA copy number reconstruction by error corrected circulating tumour DNA sequencing .